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T he control of human immunodefi ciency virus (HIV) type 1 entry, reverse transcription, integration, expres-
sion and production is operated by distinct molecular mech-
anisms, which have been targeted by antiretroviral therapy. 
Among these mechanisms, nuclear factors, such as NF-κB 
and 45/39kD CCAAT/enhancer-binding protein-β (C/EBPβ) 
isoforms, are important in regulating HIV-1 expression 
(Griffi n et al., 1989; Henderson et al., 1996). In addition, 
several transcription factors can repress virus transcription, 
often by binding to specifi c sequences contained in the vi-
rus long terminal repeat (LTR) (Patarca et al., 1988; Sub-
ler et al., 1994; Ray & Srinivas, 1997; Weiden et al., 2000; 
Cicala et al., 2002; Hayes et al., 2002). Recently, we have 
shown that the transcriptional factor OTK18 is induced by 
and suppresses HIV-1 infection in mononuclear cells (Carl-
son et al., 2004a). OTK18 is classifi ed as a transcription 
factor as it contains 13 C2H2-type DNA-binding zinc-fi nger 
motifs (Saito et al., 1996). C2H2 zinc-fi nger motifs are ca-
pable of binding to a wide range of DNA sequences, includ-
ing the HIV-1 LTR (Wu et al., 1995; Isalan et al., 2001). 
We have demonstrated previously that one putative antivi-
ral mechanism of OTK18 involves direct suppression of the 
LTR (Carlson et al., 2004a). Mutational analyses revealed 
that the suppressive activity of OTK18 lies within aa 26–89. 
This region has homology to a family of zinc-fi nger proteins 
containing the Krüppel-associated box (KRAB) motif, a re-
pression domain encoded by numerous transcription factors. 
Pengue et al. (1995) found that the KRAB domain fused to 
HIV-1 Tat was able to repress basal HIV-1 promoter activ-
ity in HeLa cells. This fi nding was supported further by the 
demonstration that a KRAB-containing tetracycline-binding 
protein can suppress HIV-1 replication through randomly 
integrated tetracycline-response elements within the HIV-1 
genomic sequence (Herchenroder et al., 1999). In addition, 
Reynolds et al. (2003) reported that a genetically engineered 
KRAB domain containing a C2H2-type
 zinc-fi nger protein 
could suppress Tat-mediated HIV-1 LTR activity, thereby 
making it an attractive candidate for antiretroviral therapy 
(Reynolds et al., 2003). In this context, OTK18 is the fi rst 
KRAB-containing C2H2 zinc-fi nger protein expressed en-
dogenously in macrophages that has antiviral activity. Inter-
estingly, OTK18 is expressed specifi cally in the cytosol of 
brain mononuclear phagocytes in severe HIV-1 encephalitis 
and may serve as a ‘surrogate’ marker for HIV-1-associated 
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Abstract : It has previously been shown by our laboratory that OTK18, a human immunodefi ciency virus (HIV)-inducible 
zinc-fi nger protein, reduces progeny-virion production in infected human macrophages. OTK18 antiviral activity is me-
diated through suppression of Tat-induced HIV-1 long terminal repeat (LTR) promoter activity. Through the use of LTR-
scanning mutant vectors, the specifi c regions responsible for OTK18-mediated LTR suppression have been defi ned. Two 
different LTR regions were identifi ed as potential OTK18-binding sites by an enhanced DNA–transcription factor ELISA 
system; the negative-regulatory element (NRE) at –255/–238 and the Ets-binding site (EBS) at –150/–139 in the LTR. 
In addition, deletion of the EBS in the LTR blocked OTK18-mediated LTR suppression. These data indicate that OTK18 
suppresses LTR activity through two distinct regulatory elements. Spontaneous mutations in these regions might enable 
HIV-1 to escape from OTK18 antiretroviral activity in human macrophages.
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dementia (Carlson et al., 2004b). Elucidation of OTK18-
binding sequences within the HIV-1 LTR is critical for the 
molecular characterization of OTK18 antiviral activity. 
In this study, we employed all 27 LTR promoter linker-
scanning mutants fused to the luciferase gene to screen for 
potential OTK18 response elements in the LTR (–453/+18) 
of the HXB2 clone (Zeichner et al., 1991). The linker-scan-
ning mutants consecutively replaced 18 bp of wild-type se-
quence with an NdeI–XhoI–SalI(NXS) polylinker (CATAT-
GCTCGAGGTCGAC) across the U3 and R regions. 
Human embryonic kidney 293 cells (105 cells per well on 
24-well plates; Fisher Scientifi c) were co-transfected with 
the LTR-scanning mutant luciferase vectors (300 ng), Tat1–
72 expression vector (pSV2Tat72, 50 ng) (Subramani et al., 
1981), a Renilla luciferase reference construct (pTK-RL, 
50 ng) and the OTK18 expression vector (pcDNA-OTK18, 
1 μg) by using GenePorter (Gene Therapy Systems) as de-
scribed previously (Carlson et al., 2004a). Forty-eight 
hours after transfection, cells were collected and luciferase 
activity was measured by using a luminometer (Berthold 
Systems Inc.) using a Dual-Luciferase kit (Promega). As 
shown in Table 1, we identifi ed six regions (A3, A8, A10, 
A12, B1 and B6, corresponding to –417/–400, –327/–310, 
–291/–274, –255/–238, –237/–220 and –147/–130), which 
were resistant to the OTK18-mediated gene suppression in 
the presence of Tat. These codes correspond to the original 
codes by Zeichner et al. (1991). 
 The binding of OTK18 to each of these six regions 
was tested by a novel DNA–transcription factor ELISA, 
which is about tenfold more sensitive than conventional 
electromobility gel-shift analysis (EMSA). Development of 
such a technique was necessary, as binding of OTK18 to 
double-stranded oligonucleotides corresponding to the re-
gions was too weak to be examined by conventional EMSA 
(data not shown). For that purpose, we generated a baculo-
virus expressing 6xHis-Express-tagged full-length OTK18 
by in-frame insertion of the full-length OTK18 gene into 
the pBlueBacHis2A vector (Invitrogen) at the BamHI site. 
The resultant vector (pBlueBacHis2A-OTK18) was in-
serted into Bac-N-Blue Autographa californica multiple 
nucleopolyhedrovirus DNA by homologous recombination 
according to the manufacturer’s protocol. Infection of Sf9 
insect cells with the optimized titre of OTK18 baculovirus 
resulted in expression of recombinant OTK18 at 84 h post-
infection, detected as a 75 kDa protein (data not shown). 
OTK18 protein was collected specifi cally from the nuclear-
extract fraction, which we used for subsequent experiments 
as control nuclear extract. 
The DNA–transcription factor ELISA method was 
originally described by Reynolds et al. (2003) and is avail-
able commercially as the colorimetric ELISA TransAM kit 
(Active Motif). To enhance the sensitivity of the original 
protocol, we incorporated luminol-based conversion of hy-
drogen peroxidase activity to chemiluminescence by us-
ing SuperSignal ELISA Pico chemiluminescent substrate 
(Pierce) instead of conventional chromogenic development. 
As shown in Figure 1, the colorimetric ELISA shows a sta-
tistically signifi cant difference between a non-specifi c oli-
gonucleotide (control) and the HIV-1 LTR oligonucleotide 
A8 in the presence of OTK18-containing nuclear extract 
from 0.5 to 5 μg input (Figure 1a), but the signal-to-noise 
(S/N) ratio is 1.31–1.41 and Z' factors are –5.64 to 0.045. 
In the case of our luminescence system, there is statisti-
cal signifi cance between two groups from 0.5 to 5 μg in-
put (Figure 1b), with an S/N ratio of 1.83–2.59 and Z′ fac-
tors of –0.88 to 0.85, which was calculated as described by 
Zhang et al. (1999). As a higher S/N ratio and Z′ factor in-
dicate suitability of the assay system, we conclude that our 
luminescence system is superior to the colorimetric sys-
tem, and we chose 2 μg nuclear extract for the following 
experiment. 
The OTK18-binding activity to each element and 
its sensitivity to cold probe ranging from 1x to 100x was 
tested (Figure 1c). The oligonucleotide pairs used for dou-
ble-stranded DNA probes are A3 [biotin-(Nx100)-CCTT-
GATCTGTGGATCTA and TAGATCCACAGATC AAGG], 
A8 [biotin-(Nx100)-TGGATGGTGCTACAAGCT and 
AGCTTGTAGCACCATCCA], A10 [biotin-(Nx100)-
GAAGTTAGAAGAAGCCAA and TTGGCTTCTTCTAA-
CTTC], A12 [biotin-(Nx100)-CTTGTTACACCCTGTGAG 
and CTCACAGGGTGTAACAAG], B1 [biotin-(Nx100)-
CCTGCATGGAATGGATGA and TCATCCATTCCAT-
GCAGG], B6 [biotin-(Nx100)-TCCGGAGTACTTCA-
AGAA and TTCTTGAAGTACTCCGG] and EBS 
[biotin-(Nx100)-CATCCGGAG and CTCCGGATG]. 
OTK18 binding was specifi c, as signifi cant binding oc-
curred only in the presence of OTK18-infected cell lysate 
and not in the presence of lysis buffer alone or uninfected 
cell lysate (Figure 1d). Whilst regions A3, A8 and B1 dem-
onstrated signifi cant binding to OTK18, none of them was 
outcompeted signifi cantly by cold probes in a dose-depen-
dent manner (Figure 1d). Only the A12 and EBS elements 
showed signifi cant binding to OTK18, which was outcom-
peted by cold probes. The B1 element showed OTK18 
binding, but was not outcompeted by cold probe, and B6, 
which contains partial EBS sequence, had no binding activ-
ity. In addition, none of the binding was outcompeted by up 
to 100-fold excess of single-stranded oligonucleotides cor-
responding to the binding sequence, suggesting its specifi c-
ity to double-stranded DNA (data not shown). These data 
indicate that the A12 and EBS elements are potential spe-
cifi c OTK18-binding sites on the HIV-1 LTR. 
The EBS is known to be an important response ele-
ment for the cooperative interaction of Ets-1 with the up-
stream stimulatory factor (USF)-1 in HIV-1 enhancer activ-
ity (Sieweke et al., 1998). As the B6 region does not cover 
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EBS completely, we created an HXB2-derived LTR lucif-
erase vector lacking EBS (–150/–139) (pLTRΔEBS-Luc) 
with a modifi ed QuikChange II site-directed mutagenesis 
kit (Stratagene) using oligonucleotide pairs and tested its 
promoter activity in the presence/absence of HIV-1 Tat and 
OTK18 in 293 cells (Figure 2). Unexpectedly, pLTRΔEBS-
Luc showed enhanced luciferase activity in the presence of 
Tat and OTK18 (second column) compared with Tat alone 
(fi rst column). Tat-activated luciferase activity of the orig-
inal LTR-Luc, on the other hand, was suppressed signifi -
cantly by OTK18 (Figure 2b). This suggested that EBS is a 
critical element for the OTK18-mediated LTR suppression 
and that OTK18 has a dual regulatory function in the HIV-1 
LTR, dependent on specifi c binding regions (see below). As 
the proximal promoter region between nucleosomes nuc0 
and nuc1, where EBS is located, has been established as a 
critical regulatory region, EBS is an important site for the 
suppressive effect of OTK18. All of the above data indicate 
that EBS (–150/–139) is the primary OTK18 response ele-
ment on the HIV-1 LTR. 
We have shown previously that the transcriptional fac-
tor OTK18 suppresses both HIV-1 Tat-mediated LTR acti-
vation in vitro and HIV-1 replication in human monocyte-
derived macrophages (MDMs) (Carlson et al., 2004a). 
However, the response element for OTK18 suppression 
has not been determined. We have shown that OTK18 in-
teracts with two distinct regions on the HIV-1 LTR, the 
NRE and EBS regions, by using LTR-scanning mutants 
and EMSA and through more defi ned subcloning/deletional 
analyses. Multiple regions of the NRE have been reported 
to downregulate HIV transcription (Garcia et al., 1987). 
Specifi cally, NRE (–182/–153) contains a binding site for 
the nuclear factors USF (Sawadogo et al., 1988), NFIL-6 
(Tesmer et al., 1993) and human GATA-3 (Yang & Engel, 
1993; Galio et al., 1999). Furthermore, NRE (–220/–160) 
binds to nuclear matrix proteins and inhibits NF-κB activ-
ity (Hoover et al., 1996). However, no proteins have been 
identifi ed that bind to NRE (–255/–238). Thus, OTK18, to 
the best of our knowledge, is the fi rst cellular protein to be 
shown to interact with this specifi c region of the NRE and 
suppress the HIV-1 LTR. 
A number of mutations were reported at this region 
in LTRs derived from human genomic DNA of HIV-1-in-
fected patients. Estable et al. (1996) reported LTR-prox-
imal sequences from 42 HIV-1-infected cases ranging 
from stage I to IV patients (World Health Organization 
Table 1. Suppression of LTR linker-scanning mutants by OTK18
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staging I–IV). Although they concluded that the Ets core 
sequence (ATCCG) was highly conserved, 25 of a total 
of 60 LTR sequences from the 42 cases were mutated in 
the Ets-1 element. The Ets core sequence was highly con-
served in non-B subtypes (De Arellano et al., 2005). We 
have also examined the available LTR depository at the 
Los Alamos HIV sequence database for LTRs of A, B, C 
and D subtypes. The conservation of ETS core sequence 
(ATCCG) was 19/19 (100 %, A), 45/48 (94 %, B), 73/74 
(97 %, C) and (90 %, D). 
Figure 1. DNA ELISA screening for binding of OTK18 to HIV-1 LTR regions. (a, b) Improved chemiluminescent method for DNA–
transcription factor ELISA. Sensitivity of two methods, conventional colorimetry (a) and chemiluminescence (b), was compared by 
using varying amounts of OTK18 protein extracts bound to a negative-control oligonucleotide (empty bars) or a double-stranded 
oligonucleotide corresponding to the A8 region of the HIV-1 LTR region (fi lled bars). Statistical analysis was performed by using 
one-way ANOVA to compare binding of each amount of extract with the binding of the negative-control oligonucleotide for the cor-
responding amount of extract (*P<0.001; §P<0.05). (c) Six regions of the HIV-1 LTR (A3–B6 and EBS) were screened for specifi c 
binding of the OTK18 protein. Binding was compared in the presence of lysis buffer alone (no lysate, fi lled bars), uninfected Sf9 
cell lysate (uninfected lysate, shaded bars) or OTK18 baculovirus-infected lysate (OTK18 lysate, empty bars). Only the OTK18 ly-
sate showed signifi cant binding (*P<0.001 compared with no lysate or uninfected lysate). (d) Binding was tested in the presence 
of no extract (–, empty bars), extract alone with no competing oligonucleotide (0x, fi lled bars), 1x excess of the corresponding 
LTR oligonucleotide (checked bars), 5x excess oligonucleotide (diagonally hatched bars), 20x excess oligonucleotide (horizontally 
hatched bars) or 100x oligonucleotide (shaded bars). Statistical analysis was performed by using one-way ANOVA to compare 
binding of each oligonucleotide with no competitor present to the corresponding no-extract condition (#P<0.001). Statistical analy-
sis was also performed by using one-way ANOVA to compare binding of the competition conditions with the no-competitor condi-
tion for the same oligonucleotide (†P<0.01; #P<0.001). NC, Negative control; RLU, relative luciferase units.
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The common Ets sequence was TGCATCCGGAG (89 
% in A, 73 % in B, 3 % in C and 38 % in D), followed by 
TACATCCGGGAG (5 % in A, 4 % in B, 77 % in C and 13 
% in D). The most striking difference is the specifi c dom-
inance of TACATCCGGGAG in subtype C, which will be 
worthwhile to pursue for future study (the mutation TAC 
in type C is at position –149, whereas the beginning of the 
core Ets sequence is at –147). Further investigation is re-
quired to understand whether LTRs derived from different 
subtypes impact their suppression by OTK18 and if such an 
impact is attributed to the difference in the Ets sequence. 
The upregulation of LTRΔEBS by OTK18 in the pres-
ence, but not in the absence, of Tat is unexpected, but it in-
dicates that OTK18 may have a dual role in LTR regula-
tion. We have found previously that there are two forms of 
OTK18 (Carlson et al., 2004a), which we defi ne as 75 kDa 
OTK18α and 65 kDa OTK18β. OTK18β lacks the KRAB-
A box and may not act as a transcriptional suppressor. 
Thus, we believe that the dual gene regulation conferred 
by OTK18α and OTK18β may arise due to the presence 
or absence of different homology domains in these differ-
ent OTK18 isoforms. Further study is necessary in order 
to characterize the expression of these OTK18 isoforms in 
MDMs and their respective roles in HIV-1 replication and 
LTR regulation. 
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